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Introduction {#jth14258-sec-0007}
============

FactorÂVIIâactivating protease (FSAP) is a plasma serine protease targeting various substrates. FSAP is mainly produced by the liver, and is present in the circulation as an inactive proenzyme. Activation is triggered by histones released from apoptotic or necrotic cells [1](#jth14258-bib-0001){ref-type="ref"}. The protein was initially separately shown to be involved in fibrinolysis, as an activator of singleâchain proâurokinase, and as an activator of FVII [2](#jth14258-bib-0002){ref-type="ref"}, [3](#jth14258-bib-0003){ref-type="ref"}, [4](#jth14258-bib-0004){ref-type="ref"}. More recently, FVII was recognized as a poor FSAP substrate [5](#jth14258-bib-0005){ref-type="ref"}, [6](#jth14258-bib-0006){ref-type="ref"}, and tissue factor pathway inhibitor (TFPI) was identified as a novel substrate. In line with this, impaired FSAP modulation of TFPI levels was suggested as an explanation for the defective thrombus formation observed in mice made deficient for FSAP (FSAP^â/â^) [7](#jth14258-bib-0007){ref-type="ref"}. Other studies have shown that FSAP has a role not only in vascular compartments [8](#jth14258-bib-0008){ref-type="ref"}, [9](#jth14258-bib-0009){ref-type="ref"}, [10](#jth14258-bib-0010){ref-type="ref"}, but also in liver fibrosis [11](#jth14258-bib-0011){ref-type="ref"}, [12](#jth14258-bib-0012){ref-type="ref"}, inflammation [13](#jth14258-bib-0013){ref-type="ref"}, [14](#jth14258-bib-0014){ref-type="ref"}, [15](#jth14258-bib-0015){ref-type="ref"}, [16](#jth14258-bib-0016){ref-type="ref"}, and cancer [17](#jth14258-bib-0017){ref-type="ref"}, [18](#jth14258-bib-0018){ref-type="ref"}. *InÂvivo* experiments in wildâtype and FSAP^â/â^ mice support a role for FSAP in vascular remodeling, liver fibrosis, neointima formation, and arteriogenesis [11](#jth14258-bib-0011){ref-type="ref"}, [19](#jth14258-bib-0019){ref-type="ref"}, [20](#jth14258-bib-0020){ref-type="ref"}, [21](#jth14258-bib-0021){ref-type="ref"}.

Epidemiological studies have shown that circulating FSAP activity is increased in women as compared with men, and is further enhanced by pregnancy or the use of oral contraceptives [22](#jth14258-bib-0022){ref-type="ref"}, [23](#jth14258-bib-0023){ref-type="ref"}, [24](#jth14258-bib-0024){ref-type="ref"}. FSAP activity is also increased in subjects with deep vein thrombosis [25](#jth14258-bib-0025){ref-type="ref"} orÂwith coronary heart disease [26](#jth14258-bib-0026){ref-type="ref"} as compared with controls. We have found that traditional vascular risk factors explain very little of the variation in plasma FSAP activity, i.e. \<Â10% in healthy individuals [27](#jth14258-bib-0027){ref-type="ref"}. We have also reported on increased FSAP activity in ischemic stroke cases as compared with controls [27](#jth14258-bib-0027){ref-type="ref"}. Furthermore, a region near the FSAPâencoding gene hyaluronanâbinding proteinÂ2 (*HABP2*) was recently identified as being associated with youngâonset stroke [28](#jth14258-bib-0028){ref-type="ref"}.

An early study of interindividual plasma levels of FSAP in healthy subjects discovered individuals with markedly reduced FSAP activity that was not related to antigen levels [23](#jth14258-bib-0023){ref-type="ref"}. Low levels of FSAP activity were found to be associated with the minor allele of the soâcalled MarburgâI (MI) singleânucleotide polymorphism (SNP) (rs7080536), which introduces an amino acid change, Gly534Glu (NP_004123.1), in the FSAP protein [29](#jth14258-bib-0029){ref-type="ref"}. The MIâSNP has been associated with several disease processes, such as carotid stenosis [30](#jth14258-bib-0030){ref-type="ref"}, stroke [31](#jth14258-bib-0031){ref-type="ref"}, and liver fibrosis [12](#jth14258-bib-0012){ref-type="ref"}. Associations between the MIâSNP and venous thrombosis have also been reported [32](#jth14258-bib-0032){ref-type="ref"}, [33](#jth14258-bib-0033){ref-type="ref"}, but inconsistent results do exist [25](#jth14258-bib-0025){ref-type="ref"}, [34](#jth14258-bib-0034){ref-type="ref"}, [35](#jth14258-bib-0035){ref-type="ref"}, [36](#jth14258-bib-0036){ref-type="ref"}.

To our knowledge, only three studies have searched for genetic variants associated with FSAP activity, and these studies were restricted to variants within *HABP2* [16](#jth14258-bib-0016){ref-type="ref"}, [27](#jth14258-bib-0027){ref-type="ref"}, [29](#jth14258-bib-0029){ref-type="ref"}. We hypothesized that there are additional genetic variants that contribute to the variation in circulating FSAP activity. Hence, we set out to test this hypothesis by conducting the first genomeâwide association study (GWAS) of this quantitative trait. We used a genotyping platform that is enriched with exome content, and searched for both common and rare genetic variants associated with FSAP activity.

Methods {#jth14258-sec-0008}
=======

Study design {#jth14258-sec-0009}
------------

This study included 3230 participants from the MalmÃ Diet and Cancer (MDC) study and the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS).

The MDC study is a populationâbased prospective study that has been described in detail elsewhere [37](#jth14258-bib-0037){ref-type="ref"}. In brief, all men and women living in the MalmÃ area in southern Sweden and born in 1923â1950 were invited to participate. The participation rate was 41% [38](#jth14258-bib-0038){ref-type="ref"}. The present study is based on the MDC Cardiovascular Cohort, which randomly selected participant from the MDC study [39](#jth14258-bib-0039){ref-type="ref"}. We included subjects without both prevalent (i.e. at baseline) and incident cardiovascular disease (CVD) with biobanked plasma available for FSAP activity measurements (*n*Â=Â2030).

The SAHLSIS is a caseâcontrol study for which FSAP activity has been reported [27](#jth14258-bib-0027){ref-type="ref"}. In brief, 600 patients with ischemic stroke at ages 18â69Âyears were consecutively recruited at stroke units in western Sweden [40](#jth14258-bib-0040){ref-type="ref"}. Controls (*n*Â=Â600) were selected from populationâbased health surveys or registers to match the cases with regard to age, sex, and geographical region [40](#jth14258-bib-0040){ref-type="ref"}. Only control subjects without a history of CVD or signs of ischemic heart disease on electrocardiogram were included [41](#jth14258-bib-0041){ref-type="ref"}.

Sample sizes and baseline characteristics for the two studies are summarized in TableÂ[1](#jth14258-tbl-0001){ref-type="table"}. The studies were approved by the ethics committee at the respective universities. All participants or their next of kin gave informed consent.

###### 

Characteristics of participants

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                      MDC study             SAHLSIS                                             Total
  ------------------------------------------------------------------- --------------------- --------------------------------------------------- ---------------------------------------------
  Ischemic stroke cases, *n* (%)                                      0 (0)                 600 (50)                                            600 (18)

  Age (years), median (IQR)                                           58 (53â63)            59 (52â65)                                          58 (52â63)

  Male sex, *n* (%)                                                   797 (39)              770 (64)                                            1567 (49)

  Hypertension[\*](#jth14258-note-0003){ref-type="fn"}, *n* (%)       1227 (60)             578 (48)                                            1805 (56)

  Diabetes mellitus[â](#jth14258-note-0003){ref-type="fn"}, *n* (%)   170 (8)               147 (12)                                            317 (10)

  Current smoking, *n* (%)                                            429 (21)              342 (29)                                            771 (24)

  Hyperlipidemia[â](#jth14258-note-0003){ref-type="fn"}, *n* (%)      1822 (90)             816 (68)                                            2638 (82)

  BMI (kgÂm^â2^), median (IQR)                                        25.3 (23.1â27.7)      26.0 (23.8â28.7)                                    25.5 (23.4â28.2)

  hsCRPÂ (mgÂL^â1^), median (IQR)                                     1.2 (0.6â2.7)         1.9 (1.0â4.1)                                       1.5 (0.7â3.2)

  FSAP activity (mUÂml^â1^), median (IQR)                             938 (778â1100)        1152 (981â1334)                                     1008 (822â1192)

  Genotyping platform                                                 HumanOmniExpress\     HumanOmniExpress\                                   Imputed to the UK10KÂ+Â1000 Genomes Phase 3
                                                                      Exome BeadChip v1.0   Exome BeadChip v1.0, and HumanOmni 5M\              
                                                                                            Exome v1.0[Â](#jth14258-note-0003){ref-type="fn"}   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; FSAP, factorÂVIIâactivating protease; hsCRP, highâsensitivity Câreactive protein; IQR, interquartile range; MDC, MalmÃ Diet and Cancer; SAHLSIS, Sahlgrenska Academy Study on Ischemic Stroke. \*Hypertension was defined as pharmacological treatment for hypertension and/or a systolic blood pressure of âÂ160ÂmmÂHg and/or a diastolic blood pressure of âÂ90ÂmmÂHg. âDiabetes mellitus was defined as dietary or pharmacological treatment for diabetes and/or a fasting glucose level of âÂ7.0ÂmmolÂL^â1^ or a fasting blood glucose level of âÂ6.1ÂmmolÂL^â1^. âHyperlipidemia was defined as pharmacological treatment for hyperlipidemia and/or a total fasting serum cholesterol level of \>Â5.0ÂmmolÂL^â1^ and/or an LDL level of \>Â3.0ÂmmolÂL^â1^. ÂhsCRP levels in the two studies were determined as described previously [61](#jth14258-bib-0061){ref-type="ref"}, [62](#jth14258-bib-0062){ref-type="ref"}. ÂIncluded in the NINDS Stroke Genetic Network study, *n*Â=Â444 ischemic stroke cases.
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FSAP activity measurement {#jth14258-sec-0010}
-------------------------

Venous blood samples were collected in tubes containing 10% by volume of 0.13ÂmolÂL^â1^ sodium citrate. Aliquots of plasma were stored at âÂ80ÂÂC. For the prospective MDC study, blood samples were drawn during the baseline examinations in 1991â1996. For the SAHLSIS, blood sampling was performed in 1998â2003; at enrollment for controls, and at 3âmonth followâup for cases [27](#jth14258-bib-0027){ref-type="ref"}, [40](#jth14258-bib-0040){ref-type="ref"}. Plasma levels of FSAP activity were measured with an immunocapture activity test, as previously described [23](#jth14258-bib-0023){ref-type="ref"}, [27](#jth14258-bib-0027){ref-type="ref"}. These measurements were performed in 2010 and 2014 for the SAHLSIS and the MDC study, respectively. The interassay and intraâassay coefficients of variation (CVs) for FSAP activity were 14.7% and 4.7%, respectively, in the SAHLSIS, as reported in [27](#jth14258-bib-0027){ref-type="ref"}, and the interassay CV was 8.2% in the MDC study. FSAP activity values followed a normal distribution, and were not transformed for analysis.

Genotyping, imputation, and quality control (QC) {#jth14258-sec-0011}
------------------------------------------------

DNA was extracted from whole blood, and genotyping was performed with either the HumanOmniExpress Exome BeadChip v1.0 at the Broad Institute or the HumanOmni 5M Exome v1.0 as part of the Stroke Genetics Network (SiGN) study (Illumina, San Diego, CA, USA), and is described in detail elsewhere [42](#jth14258-bib-0042){ref-type="ref"}, [43](#jth14258-bib-0043){ref-type="ref"}. These arrays have anÂoverlap of the Omni content (coverage of common genomeâwide variation) and of the exome content (240k probes). The QC criteria were filtering for sex mismatch, call rate of \<Â0.95, identical by descent sharing (\>Â0.375), population outliers, excess autosomal heterozygosity, and deviation from HardyâWeinberg equilibrium (*PÂ*\<*Â*10^â3^). After separate QC for each dataset had been performed, genotypes available on both platforms were merged and subjected to repeat QC according to the above criteria. Chromosomes were phased by the use of [shapeit2]{.smallcaps} (v2.r790 [44](#jth14258-bib-0044){ref-type="ref"}) and imputed against the UK10KÂ+Â1000 Genomes PhaseÂ3 reference panel at the Sanger Imputation Service mapped to hg19 [45](#jth14258-bib-0045){ref-type="ref"}. Approximately 10ÂÃÂ10^6^ variants with a minor allele frequency (MAF) of \>Â0.01 and an information score of \>Â0.3 were brought forward for analysis. After QC, the total number of subjects included in the analyses was 3126.

Genomeâwide association analyses {#jth14258-sec-0012}
--------------------------------

Genotypeâphenotype association analyses were performed according to a prespecified analysis plan on variants with an MAF of \>Â0.01. The association between variants and FSAP activity was assessed with a linear model, on the assumption of an additive effect of each risk allele, with [plink]{.smallcaps} versionÂ1.9. All analyses were adjusted for age, sex, study (i.e. the MDC study or the SAHLSIS to adjust for studyâassociated biases such as variations in year of sample collection, plasma storage time, and batch effects on FSAP activity measurements), and ischemic stroke caseâcontrol status. Selected MDC study participants were free of both prevalent and incident stroke, so all MDC study subjects were assigned control status. The thresholds of genomeâwide significance and suggestive association were set at the conventional levels of *PÂ*=*Â*5ÂÃÂ10^â8^ and *PÂ*=*Â*1ÂÃÂ10^â5^, respectively. On the basis of our sample size and on the assumption of an additive model, the minimal effect size (*Î*âcoefficient) per allele that is detectable with 80% power is 0.27 for a MAF of 10%, 0.37 for a MAF of 5%, and 0.78 for a MAF of 1%. Conditional analyses were performed on the lead SNPs for their respective chromosomal regions.

Geneâbased analyses {#jth14258-sec-0013}
-------------------

All directly genotyped functional variants (missense, nonsense and splice variants) with a MAF of \<Â0.05 that passed QC were included in the geneâbased tests. Genes were required to contain at least two variants to be included in the analysis (71Â134 variants in 11Â425 genes in total). Geneâbased tests were performed with the optimal combination of the sequence kernel association test and the burden test (SKATâO) [46](#jth14258-bib-0046){ref-type="ref"} in [r]{.smallcaps} package [skat]{.smallcaps} v.1.0.7, with adjustment for age, sex, caseâcontrol status, and study. A Bonferroniâcorrected *P*âvalue threshold of 4.4ÂÃÂ10^â6^ was used (0.05/11Â425 genes).

Owing to the association of multiple rare variants in *HAPB2* with FSAP activity, we removed one rare variant at a time and repeated SKATâO to determine the impact of each variant on the geneâbased association.

Genotyping of variants associated with FSAP activity in additional cohorts {#jth14258-sec-0014}
--------------------------------------------------------------------------

The MIâSNP, rs35510613 and rs41292628 were genotyped in 665 subjects from the Venous Thromboembolism in Pregnancy (VIP) study from Norway [47](#jth14258-bib-0047){ref-type="ref"}, [48](#jth14258-bib-0048){ref-type="ref"} and in 276 healthy subjects from the Danish Risk Score (DanRisk) study [49](#jth14258-bib-0049){ref-type="ref"}, which have measured FSAP activity with the same assay as was used in the present study. In brief, the VIP study included 313 women with pregnancyârelated venous thromboembolism and 353 controls. The DanRisk study included 155 women and 121 men born in either 1949 or 1959. Genotyping was performed at the University of Oslo (Norway) and at LGC genomics (UK) with KASPar genotyping chemistry. The studies were approved by the respective Norwegian and Danish regional committees on medical health research ethics, and all participants gave their written informed consent to participate.

Annotation and functional prediction of variants {#jth14258-sec-0015}
------------------------------------------------

Genetic variants of interest were visualized in the UCSC Genome Browser, with regional association plots [50](#jth14258-bib-0050){ref-type="ref"}, in HaploReg v4.1 [51](#jth14258-bib-0051){ref-type="ref"}, in the Genbank SNP database, and in the Exome Aggregation Consortium (ExAC) [52](#jth14258-bib-0052){ref-type="ref"}. Prediction of functional effects of SNPs (PolyPhen and SIFT) were retrieved from the ExAC. Genetic variants associated with gene expression levels were identified in the GenotypeâTissue Expression Project (GTEx), and expression levels were analyzed in the GTEx and in BioGPS [53](#jth14258-bib-0053){ref-type="ref"}. Genetic variants with a correlation with lead SNPs (*r* ^2^Â\>Â0.6) were identified in HaploReg v4.1, and additional functional predictions were assessed with RegulomeDB [54](#jth14258-bib-0054){ref-type="ref"}.

Cell culture {#jth14258-sec-0016}
------------

Mouse primary hepatocytes were isolated from BALB/c mice by collagenase perfusion as described previously [55](#jth14258-bib-0055){ref-type="ref"}. Hepatocytes were cultivated in Dulbecco\'s modified Eagle\'s medium High Glucose/F12 (1Â:Â1) supplementedÂwith 5Âm[m]{.smallcaps} sodium pyruvate (Thermo Fisher Scientific, Fermentas, Rockford, IL, USA), 10Âm[m]{.smallcaps} HEPES (SigmaâAldrich, St. Louis, MO, USA), 1Âm[m l]{.smallcaps}âglutamine (Thermo Fisher Scientific), 0.05% (v/v) NaH~2~CO~3~ (SigmaâAldrich), 10Âm[m]{.smallcaps} glucose (SigmaâAldrich), 10% fetal bovine serum (Thermo Fisher Scientific), 10ÂunitsÂmL^â1^ penicillin, and 10ÂÎgÂmL^â1^ streptomycin (Invitrogen, Darmstadt, Germany). Cells were maintained in a humidified atmosphere of 5% CO~2~ at 37ÂÂC, and treated with 8â(4âchlorophenylthio)adenosine 3â,5ââcyclic monophosphate sodium (8âCPT) or forskolin (both from SigmaâAldrich).

RNA isolation and quantitative PCR analysis {#jth14258-sec-0017}
-------------------------------------------

Total RNA was extracted from hepatocytes with the total RNA Miniprep Kit (SigmaâAldrich). Reverse transcription was performed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). For realâtime PCR, the SensiMix SYBR Kit (Bioline, Luckenwalde, Germany) was used. *Habp2* transcript levels were analyzed as described previously, and normalized against the reference gene *Gusb* [55](#jth14258-bib-0055){ref-type="ref"}. Primer sequences are shown in TableÂ[2](#jth14258-tbl-0002){ref-type="table"}.

###### 

List of PCR primers used for realâtime PCR of *Habp2*

  Target gene   Forward primer sequence   Reverse primer sequence
  ------------- ------------------------- -------------------------
  *Gusb*        AAAATGGAGTGCGTGTTGGGT     CCACAGTCCGTCCAGCGCCTT
  *Habp2*       TTCCCGACACAGACGGAGA       GTCGTCCGGACCTATTTCA

*Gusb*, the gene encoding Îâglucuronidase.
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Statistical analysis {#jth14258-sec-0018}
--------------------

We used linear regression to determine the amount of variance in FSAP activity explained by the covariates included in the GWAS model, i.e. age, sex, caseâcontrol status, and study. We then performed a model conditioned on these covariates to determine the remaining variance explained by a particular SNP or SNP combination, or by traditional vascular risk factors (hypertension, diabetes mellitus, smoking, and hyperlipidemia), body mass index, and highâsensitivity Câreactive protein (hsCRP, logâtransformed). Associations between FSAP activity and genotypes in the VIP and DanRisk studies were analyzed with linear regression adjusting for age, sex, and caseâcontrol status, or with Student\'s *t*âtest, as appropriate. Changes in *Habp2* transcript levels in response to treatment as compared with control were analyzed with Student\'s *t*âtest.

Results {#jth14258-sec-0019}
=======

We conducted a GWAS and evaluated rare and lowâfrequency functional variants by using geneâbased tests in 3230 individuals of predominantly northern European ancestry to identify genetic loci influencing circulating FSAP activity. Characteristics of participants and genotyping arrays are summarized in TableÂ[1](#jth14258-tbl-0001){ref-type="table"}. The majority of the participants (i.e. \>Â80%) were populationâbased and free of CVD. Subjects homozygous for the minor allele of the MIâSNP had approximately fiveâfold lower FSAP activity than subjects homozygous for the major allele (TableÂ[3](#jth14258-tbl-0003){ref-type="table"}), which is in line with previous reports [56](#jth14258-bib-0056){ref-type="ref"}. Above the variance in FSAP activity explained by the covariates adjusted for in the GWAS (i.e. age, sex ischemic stroke caseâcontrol status, and study), cardiovascular risk factors, anthropometrics and hsCRP explained only 3.6% of the variance in FSAP activity.

###### 

Plasma factorÂVIIâactivating protease (FSAP) activity for different MarburgâI genotypes

  Genotype   Median FSAP activity (mUÂmL^â1^)   FSAP activity IQR (mUÂmL^â1^)   No.
  ---------- ---------------------------------- ------------------------------- ------
  MI:GG      1032                               862â1208                        2898
  MI:AG      592                                510â712                         224
  MI:AA      207                                49â366                          4

IQR, interquartile range; MI, MarburgâI (rs7080536).
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GWAS {#jth14258-sec-0020}
----

After adjustment for age, sex, study, and ischemic stroke caseâcontrol status, 164 variants were genomeâwide significant, and 239 additional variants were suggestively associated with FSAP activity (Fig.Â[1](#jth14258-fig-0001){ref-type="fig"}; TableÂ[S1](#jth14258-sup-0002){ref-type="supplementary-material"}). The quantileâquantile plot for the GWAS revealed more variants with lower observed *P*âvalues than expected (Fig.Â[1](#jth14258-fig-0001){ref-type="fig"}B). The genomic control (lambda) was 1.016. Associated loci with *PÂ*\<*Â*1ÂÃÂ10^â6^ are shown in TableÂ[4](#jth14258-tbl-0004){ref-type="table"} and outlined below.

![Genomeâwide association analyses of factorÂVIIâactivating protease (FSAP) activity. (A) Manhattan plot of associations for FSAP activity. The dotted line shows genomeâwide significance (5ÂÃÂ10^â8^). The plot is truncated at a *P*âvalue of 10^â20^. (B) Quantileâquantile plot for associations. (C, D) Regional association plots of the MarburgâI (MI)âsingleânucleotide polymorphism (SNP) (rs7080536) (C) and of rs1579587 (D), which showed suggestive association (*P*Â=Â5.1ÂÃÂ10^â6^) when the 10q25 region was adjusted for MIâSNP. Linkage disequilibrium (*r* ^2^) is indicated by the color scale.](JTH-16-2024-g001){#jth14258-fig-0001}

###### 

Lead associated genetic loci (*PÂ*\<*Â*1ÂÃÂ10^â6^) for factorÂVIIâactivating protease activity

  Locus      Lead variant   Chromosome: position of lead variant in hg19   Geneârelated position             Alleles (A1/A2)   Frequency   *Î*    *P*âvalue
  ---------- -------------- ---------------------------------------------- --------------------------------- ----------------- ----------- ------ ----------------
  10q25.3    rs7080536      10: 115Â348Â046                                Missense in *HABP2*               A/G               0.037       â429   7.0ÂÃÂ10^â142^
  5p15.31    rs35510613     5: 7Â377Â210                                   Intergenic, upstream of *ADCY2*   â/G               0.77        â45    1.3ÂÃÂ10^â8^
  12q21.31   rs75809015     12: 82Â823Â136                                 Intron in *METTL25*               G/A               0.012       194    2.1ÂÃÂ10^â7^
  17q25.3    rs62073440     17: 81Â005Â762                                 Intron in *B3GNTL1*               C/T               0.11        59     4.6ÂÃÂ10^â7^
  7p11.2     rs373067567    7: 57Â749Â605                                  Intergenic                        CAT/C             0.61        â37    7.0ÂÃÂ10^â7^
  16q24.1    rs61613787     16: 84Â728Â954                                 Intergenic, upstream of *USP10*   C/T               0.014       169    8.6ÂÃÂ10^â7^

*ADCY2*, adenylate cyclaseÂ2; *B3GNTL1*, UDPâGlcNAc:beta Gal Îâ1,3â*N*âacetylglucosaminyltransferaseâlikeÂ1; *HABP2*, hyaluronanâbinding proteinÂ2; *METTL25*, methyltransferaseâlikeÂ25; *USP10*, ubiquitinâspecific peptidaseÂ10.
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The majority of the genomeâwide associations (*n*Â=Â163) were located at the 10q25 locus near *HABP2*. The strongest association was found for the MIâSNP rs7080536 (*PÂ*=*Â*7.0ÂÃÂ10^â142^; Fig.Â[1](#jth14258-fig-0001){ref-type="fig"}C).

At the 5p15 locus, rs35510613 was genomeâwide significant (*PÂ*=*Â*1.3ÂÃÂ10^â8^; Fig.Â[S1](#jth14258-sup-0001){ref-type="supplementary-material"}). This variant is located 19Âkbp upstream of the adenylate cyclaseÂ2 (*ADCY2*) gene. Two SNPs, rs12652415 and rs1609428, located in *ADCY2* introns were in linkage disequilibrium (LD) with rs35510613 (r^2^, 0.74 and 0.64; and Dâ, 0.89 and 0.96, respectively) and showed suggestive associations with FSAP activity (*PÂ*=*Â*1.1ÂÃÂ10^â6^ and *PÂ*=*Â*4.3ÂÃÂ10^â6^, respectively).

SNPs with suggestive associations with *PÂ*\<*Â*1ÂÃÂ10^â6^ were also located at 12q21 (rs75809015), 17q25 (rs62073440), 7p11 (rs373067567) and 16q24 (rs61613787) loci (TableÂ[4](#jth14258-tbl-0004){ref-type="table"}).

Above the variance in FSAP activity explained by the covariates adjusted for in the GWAS (i.e. age, sex, ischemic stroke caseâcontrol status, and study), rs7080536 explained 18.6% of the remaining variance in FSAP activity, whereas rs35510613 explained 1%. Associations for these variants were also evaluated in a stratified analysis of study participants without stroke or CVD (i.e. all MDC study subjects and SAHLSIS controls). The effect sizes for both rs7080536 and rs35510613 were similar to those in the whole sample, and the same was true when MDC subjects only were analyzed (TableÂ[S2](#jth14258-sup-0002){ref-type="supplementary-material"}).

Conditional analyses on lead SNPs {#jth14258-sec-0021}
---------------------------------

To identify independent signals within each locus, conditional analyses were performed on the lead variants with *PÂ*\<*Â*1ÂÃÂ10^â6^. At the 10q25 locus, rs1539587 remained suggestively associated after adjustment for rs7080536 (*PÂ*=*Â*5.1ÂÃÂ10^â6^). This variant is located in the neighboring nebulinârelated anchoring (*NRAP*) gene (Fig.Â[1](#jth14258-fig-0001){ref-type="fig"}D). No other suggestive associations remained.

Geneâbased analyses {#jth14258-sec-0022}
-------------------

Next, we performed geneâbased association tests by using SKATâO. Two genes were significantly associated with FSAP activity after Bonferroni correction. *HABP2* showed the strongest association (*PÂ*=*Â*8.2ÂÃÂ10^â120^), and was represented by 10 variants. *DCLRE1A* (*PÂ*=*Â*3.0ÂÃÂ10^â16^)*,* which is also located on chromosomeÂ10q25, was represented by nine variants. The geneâbased analysis was repeated for chromosomeÂ10 without the carriers of the MIâSNP, and, in this analysis, only *HABP2* remained significant (*PÂ*=*Â*8.9ÂÃÂ10^â9^). *NRAP* (*PÂ*=*Â*1.5ÂÃÂ10^â5^, represented by 22 variants) was ranked as the second most associated gene.

On testing of the contribution of each rare variant inÂ*HABP2* to the SKATâO *P*âvalue, rs41292628 (MAF ofÂ0.002), which encodes a stop codon at amino acid positionÂ203, was identified as a determinant of FSAP activity (Fig.Â[2](#jth14258-fig-0002){ref-type="fig"}). The FSAP activity in 13 carriers of thisÂstop variant was reduced as compared with that inÂnonâcarriers (IQR~rs41292628:C/T~Â=Â404â592ÂmUÂmL^â1^, IQR~rs41292628:C/C~Â=Â825â1190ÂmUÂmL^â1^, *P* ~*t*âtest~Â\<Â0.001). The association for rs41292628 was also independent of the *NRAP* rs1539587 variant (*PÂ*=*Â*2.5ÂÃÂ10^â16^) after adjustment for both the MIâSNP and rs1539587 in a linear model. In subjects homozygous for the MI major allele (MI:GG), after adjustment for GWAS covariates, 3.5% of the remaining variance in FSAP activity was explained by rs41292628, rs35510613, and rs1539587.

![Analysis for factorÂVIIâactivating protease activity associations of rare variants (minor allele frequency of \<Â5%) in *HABP2*. The âÂlog~10~(*P*âvalue) is shown from optimal combination of the sequence kernel association test and the burden test (SKATâO) of *HABP2*. For each rare variant presented in the graph, the variant was removed from the test and the *P*âvalue for the geneâbased SKATâO analysis was determined. The analyses were performed in individuals homozygous for the major allele of the MarburgâI singleânucleotide polymorphism (MIâSNP:GG). The dashed line shows the Bonferroniâcorrected threshold *P*âvalue of 0.00011 (0.05/447 genes) for geneâbased tests on chromosome 10 among MIâSNP:GGâcarrying subjects.](JTH-16-2024-g002){#jth14258-fig-0002}

Genotypes for top associated variants in the VIP and DanRisk studies {#jth14258-sec-0023}
--------------------------------------------------------------------

The genotyping success rate was \>Â95% for all variants. The known association between the MIâSNP and FSAP activity was detected in both studies (*PÂ*\<*Â*0.001). One carrier of the stop variant was identified in the VIP study (MAF~rs41292628~Â=Â0.0009) and six in the DanRisk study (MAF~rs41292628~Â=Â0.011). Similarly to the discovery cohort, carriers of the stop variant had reduced FSAP activity (VIP, FSAP~rs41292628:C/T~Â=Â770ÂmUÂmL^â1^ versus interquartile range \[IQR\]~rs41292628:C/C~Â=Â910â1210ÂmUÂmL^â1^; and DanRisk, IQR~rs41292628:C/T~Â=Â14â62% of reference plasma versus IQR~rs41292628:C/C~Â=Â60â85% of reference plasma, *P* ~*t*âtest~Â\<Â0.001). In contrast, the association for rs35510613 on the 5p15 locus was not confirmed in either the Norwegian or the Danish study (*P*Â\>Â0.2 for both).

Annotation and functional prediction of top associated variants {#jth14258-sec-0024}
---------------------------------------------------------------

For the top associated variants (TableÂ[4](#jth14258-tbl-0004){ref-type="table"}), we also evaluated expression quantitative trait locus (eQTL) presence, and the putative regulatory function of variants in LD (TablesÂ[S3](#jth14258-sup-0001){ref-type="supplementary-material"} and [S4](#jth14258-sup-0001){ref-type="supplementary-material"}). There were, in total, 12 SNPs with *r* ^2^Â\>Â0.6 with top associated variants (*PÂ*\<*Â*1ÂÃÂ10^â6^) in the CEU population dataset in the HaploReg database (TableÂ[S3](#jth14258-sup-0001){ref-type="supplementary-material"}). Of these, 11 were included in the GWAS. None of the top associated variants had a RegulomeDB score of \<Â5. For rs62073440 and for 5p15 variants in LD with the lead SNP in this region (rs1265241 and rs1609428), eQTLs were identified towards *B3GNTL1* and nonâproteinâcoding *CTDâ2296D1.5* (TableÂ[S4](#jth14258-sup-0001){ref-type="supplementary-material"}), respectively.

The missense MIâSNP is known to influence FSAP activity, and was thus not evaluated further here, apart from the *inÂsilico* annotation provided in TableÂ[S3](#jth14258-sup-0001){ref-type="supplementary-material"}. The *NRAP* rs1539587 is also a missense mutation. The estimated effect of the minor allele on NRAP protein function is deleterious and benign according to PolyPhen and SIFT, respectively. This variant is also predicted to alter a putative regulatory motif sequence (TableÂ[S3](#jth14258-sup-0001){ref-type="supplementary-material"}). In BioGPS, the *NRAP* transcript was solely expressed in heart tissue, whereas GTEx indicated high gene expression also in skeletal muscle (Fig.Â[S2](#jth14258-sup-0001){ref-type="supplementary-material"}). However, except for the genomic proximity, we could not identify any clear biological or functional link between FSAP and *NRAP*. In contrast, the 5p15 locus, containing *ADCY2*, may be of functional relevance. Adenylate cyclase catalyzes the conversion of ATP to the secondary messenger molecule cAMP. Therefore, we investigated whether cAMP modifiers influence *Habp2* expression *inÂvitro*, as described below. Given that circulating FSAP is mainly produced in the liver [2](#jth14258-bib-0002){ref-type="ref"}, hepatocytes were investigated.

*Habp2* expression in hepatocytes in response to cAMP modifiers {#jth14258-sec-0025}
---------------------------------------------------------------

In order to determine whether *Habp2* mRNA levels were affected by cAMP modifiers, primary mouse hepatocytes were incubated with 8âCPT, an activator of the downstream cAMP activatorâdependent kinase (protein kinaseÂA \[PKA\]), or with forskolin, which stimulates cAMP production. Increases in *Habp2* transcript levels were found after 48Âh of incubation with 8âCPT (*PÂ*\<*Â*0.05 for both 50ÂÎ[m]{.smallcaps} and 200ÂÎ[m]{.smallcaps}) and after 24Âh of forskolin treatment (*PÂ*\<*Â*0.05 for both 50ÂÎ[m]{.smallcaps} and 200ÂÎ[m]{.smallcaps}) relative to control (Fig.Â[3](#jth14258-fig-0003){ref-type="fig"}).

![*Habp2* expression in primary mouse hepatocytes in response to cAMP modifiers. (A) Cells were stimulated with 50ÂÎ[m]{.smallcaps} or 200ÂÎ[m]{.smallcaps} 8â(4âchlorophenylthio)adenosine 3â,5ââcyclic monophosphate sodium (8âCPT) in *n*Â=Â4 biological replicates (*n*Â=Â2 technical replicates). (B) Cells were stimulated with 20ÂÎ[m]{.smallcaps} or 50ÂÎ[m]{.smallcaps} forskolin in *n*Â=Â5 biological replicates (*n*Â=Â2 technical replicates). Data are presented as meanÂÂÂstandard error of the mean. Significance is compared with control (CTRL) at each time point \**PÂ*\<*Â*0.05; \*\**PÂ*\<*Â*0.005. FORSK, forskolin.](JTH-16-2024-g003){#jth14258-fig-0003}

Discussion {#jth14258-sec-0026}
==========

We searched for genetic factors contributing to the variation in circulating FSAP activity by using GWAS and geneâbased analysis. We identified several signals at the 10q25 locus: (i) the lead SNP in the GWAS was the wellâknown missense variant in the FSAPâencoding *HABP2* gene, i.e. MI (*P*Â=Â7.0ÂÃÂ10^â142^); (ii) suggestive significance remained for an SNP at the 10q25 locus in *NRAP* after conditioning for this MI variant; and (iii) in geneâbased analysis, *HABP2* was genomeâwide significant, an *HABP*2 stop variant was identified as an additional determinant of FSAP activity, and *NRAP* showed suggestive association. In the GWAS, we also identified a novel genomeâwide significant locus on chromosomeÂ5 with the lead SNP located upstream of *ADCY2*. Taken together, variants within *HABP2*,*NRAP* and *ADCY2* were found to explain 21.4% of the variance in FSAP activity, above the variance explained by the covariates in the GWAS (i.e. age, sex, ischemic stroke caseâcontrol status, and study). In comparison, cardiovascular risk factors, including hsCRP, explained only 3.6% of the variance in FSAP activity above the variance explained by the covariates included in the GWAS.

In the GWAS, we identified a high number of SNPs with genomeâwide significance at the 10q25 locus. The lead MIâSNP was reported to be associated with FSAP activity in 2002 [29](#jth14258-bib-0029){ref-type="ref"}, and we confirmed here that homozygous carriers of the MI variant have approximately fiveâfold lower plasma FSAP activity than nonâcarriers [56](#jth14258-bib-0056){ref-type="ref"}. We also identified additional signals at the 10q25 locus that were independent of the MIâSNP, indicating a complex genomic architecture at this locus. After conditioning on the MIâSNP, rs1539587 in the neighboring *NRAP* gene remained suggestively associated with FSAP activity. After adjustment for GWAS covariates, the amounts of FSAP activity variance explained by the MIâSNP alone and together with rs1539587 were 18.6% and 19.2%, respectively.

*HABP2* was also significantly associated with FSAP activity in the geneâbased analysis. When we omitted all MI carriers from this analysis, the association with *HABP2* remained. This association was mainly attributable to a newly identified rare variant (rs41292628), which is located in the coding region and introduces a premature stop codon at amino acid positionÂ203 (NP_004123.1). This position is before the serine protease domain of FSAP, and thus total loss of function can be expected to result from the introduction of this stop codon. Carriers of the stop variant had FSAP activity in the same range as MI variant carriers. In line with our results, a study from the Netherlands reported on an anonymous serum donor with deficient FSAP protein who was homozygous for the stop variant [16](#jth14258-bib-0016){ref-type="ref"}. As a replication effort, we genotyped 941 subjects from Norway and Denmark. We identified seven heterozygous carriers of the stop variant for whom the FSAP activities were in the same range as for MI variant carriers. Our results also indicated a northâtoâsouth gradient of increasing MAF for the stop variant. As FSAP activity has been implicated in several pathophysiological processes (recently reviewed in [57](#jth14258-bib-0057){ref-type="ref"}), and the mechanisms remain elusive, future genetic studies that take into account both the *HAPB2* MI and stop variant would be of interest. However, given the low frequency of these variants, this will require very large datasets genotyped with rare variant information (e.g. exome chips or exome sequencing).

Using the GWAS approach, we also identified a novel genomeâwide significance locus at 5p15. The lead SNP (rs35510613) is located upstream of *ADCY2* and is in high LD with two SNPs in *ADCY2* introns. The protein encoded by *ADCY2* is one of 10 adenylate cyclase isoforms that catalyzes the formation of cAMP. We have shown that there is a significant correlation between plasma levels of FSAP antigen and FSAP activity [27](#jth14258-bib-0027){ref-type="ref"}, suggesting that, apart from variants affecting the FSAP protein itself, such as the MI and stop variants, gene variants influencing FSAP expression may influence FSAP activity. There are also data indicating that *Habp2* mRNA and FSAP protein levels change in parallel [22](#jth14258-bib-0022){ref-type="ref"}, [58](#jth14258-bib-0058){ref-type="ref"}, [59](#jth14258-bib-0059){ref-type="ref"}, and experimental data from studies on hepatic rodent cells indicating that cAMP may be involved in regulating *Habp2* expression [55](#jth14258-bib-0055){ref-type="ref"}.

In order to obtain more direct information on the potential involvement of the cAMPâdependent pathway in regulating *Habp2* expression, we therefore performed *inÂvitro* studies on primary mouse hepatocytes. Using either forskolin or 8âCPT, we found increased mRNA levels of *Habp2* in these cells. Although the results from both *inÂvitro* manipulations agree with a model in which increased cAMP levels may affect *Habp2* transcription through PKA activation, direct functional characterization is needed to support a functional role for *ADCY2* in regulating FSAP.

It is also of note that we were not able to replicate the association between rs35510613 and FSAP activity in the two other, smaller, Scandinavian studies. However, the replication effort was mainly targeted at the *HABP2* stop variant, and we did not have sufficient statistical power to replicate the effect size for rs35510613. Thus, we believe that future independent replications in larger samples are warranted before further studies are performed to functionally characterize this variant.

The major strength of this study is that we analyzed \~Â10Âmillion markers spread throughout the genome, covering both common variants (assessed via GWAS) and rare variants (assessed via geneâbased testing) in 3230 wellâcharacterized individuals who were ethnically relatively homogeneous [43](#jth14258-bib-0043){ref-type="ref"}, and the majority were ascertained by populationâbased recruitment methods. This is thus the most comprehensive genetic study of circulating FSAP activity to date. However, in the context of genomeâwide association analysis, the sample size is still modest, and we thus have limited power to detect relatively small effect sizes, even for common variants. Another limitation is that we included participants with ischemic stroke, who, as a group, have increased FSAP activity as compared with controls. However, in a sensitivity analysis excluding stroke cases, we found similar effect sizes for the lead variants in *HABP2* and *ADCY2*. Another strength of the study is the use of a standardized protocol for blood sampling in both cohorts, and the fact that all samples were analyzed with the same FSAP activity assay. A limitation is that blood sampling and FSAP activity measurements were performed on different occasions. However, analysis of the largest cohort (MDC study) alone provided similar effect sizes for the top findings. We used a wellâcharacterized FSAP activity assay, but a limitation of this assay is that FSAP hydrolyzes singleâchain proâurokinase, generating urokinase plasminogen activator, the activity of which is used as a proxy for FSAP activity. It is not known whether this covers all aspects of FSAP activity. It is thus plausible that an assay with another substrate may generate somewhat different findings. However, we have shown that the MI FSAP protein has reduced activity as compared with wildâtype FSAP towards all identified substrates that we have tested so far [21](#jth14258-bib-0021){ref-type="ref"}, [56](#jth14258-bib-0056){ref-type="ref"}. With regard to the rare variant analysis, we used an exome array, so rare variants that impact on FSAP activity may remain to be discovered with exome sequence analysis. Additionally, it should be emphasized that the results were generated in a population of predominantly European ancestry, and our findings may not be generalizable to populations of different ethnicity.

We confirmed that the *HABP2* MI variant is a strong regulator of FSAP activity, and we identified and replicated a *HABP2* stop variant with a similar impact on FSAP activity. We also identified a novel locus near *ADCY2* as an additional potential regulator of circulating FSAP activity that requires future independent replication. Interestingly, the identified genetic variants explained ≈ 20% of the variation in FSAP activity, whereas cardiovascular risk factors explained \<Â4%. Additional larger genetic studies, potentially employing future novel assays for the measurement of FSAP activity [60](#jth14258-bib-0060){ref-type="ref"}, may provide further insights into the genetic regulation of this plasma protease, and thus pave the way for future studies on its role in different pathophysiological pathways.

Addendum {#jth14258-sec-0027}
========

C. Jern, S. M. Kanse, O. Melander, M. Olsson, and T. M. Stanne conceived the research design of the present study. C. Jern and A. Pedersen were responsible for the SAHLSIS (sample and phenotype contribution). G. EngstrÃm and O. Melander were responsible for the MDC study (sample and phenotype contribution). P.M. Sandset and A. F. Jacobsen were responsible for the VIP study (sample and phenotype contribution). J. J. Sidelmann and N. P. RÃnnow Sand were responsible for the DanRisk study (sample and phenotype contribution). A. MartinezâPalacian and E. Kara performed *inÂvitro* experiments and measurements of plasma FSAP activity, respectively. S. M. Kanse supervised *inÂvitro* experiments and measurements of plasma FSAP activity. E. Lorentzen, M. Olsson, and A. MartinezâPalacian performed statistical analyses. M. Olsson, T. M. Stanne, C. Jern and S. M. Kanse interpreted the data. M. Olsson and C. Jern: drafted the manuscript. S. M. Kanse, T. M. Stanne, O. Melander, G. EngstrÃm, P. M. Sandset, and J. J. Sidelmann intellectually reviewed the manuscript. All authors contributed to the last revision process and approved the version to be published.

Disclosure of Conflict of Interests {#jth14258-sec-0029}
===================================

The authors state that they have no conflict of interest.

Supporting information
======================

###### 

**Fig.ÂS1.** Regional association plot of rs35510613, which showed significant association for FSAP activity.

**Fig.ÂS2.** Tissue distributions of *NRAP* gene expression.
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**TableÂS1.** Genomeâwide (*P*Â\<Â5ÂÃÂ10^â8^) and suggestive significant loci (*PÂ*\<Â1ÂÃÂ10^â5^) for FSAP activity.

**TableÂS2.** Association of rs7080536, and rs35510613 with FSAP activity in study participants without stroke or CVD.

**TableÂS3.** Functional annotations from HaploReg 4v1, level of association with FSAP activity in present GWAS, and RegulomeDB score for top associated lead genetic variants (*P*Â\<Â1ÂÃÂ10^â6^), of rs1539587, and variants in linkage disequilibrium (LD; *r* ^2^ÂâÂ0.6 in EUR population in HaploReg 4v1) with these variants.

**TableÂS4.** Expression quantitative trait loci (eQTLs) from the GTEx Portal identified for top associated lead variants (*P*Â\<Â1ÂÃÂ10^â6^) for FSAP activity, and variants highlighted in this study.
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